TMPRSS11D and schistosomiasis: In this study, the antischistosomal activity of three commercially available HAT inhibitors, A485, C646 and curcumin was assessed, with the aim of verifying the feasibility of using SjHAT as a novel therapeutic target for schistosomiasis.